MX391789B - Anticuerpos anti-transtiretina. - Google Patents

Anticuerpos anti-transtiretina.

Info

Publication number
MX391789B
MX391789B MX2017009804A MX2017009804A MX391789B MX 391789 B MX391789 B MX 391789B MX 2017009804 A MX2017009804 A MX 2017009804A MX 2017009804 A MX2017009804 A MX 2017009804A MX 391789 B MX391789 B MX 391789B
Authority
MX
Mexico
Prior art keywords
ttr
antibodies
transthyretin
accumulation
amyloidosis
Prior art date
Application number
MX2017009804A
Other languages
English (en)
Spanish (es)
Other versions
MX2017009804A (es
Inventor
Avijit Chakrabartty
Jeffrey N Higaki
Tarlochan S Nijjar
Original Assignee
Novo Nordisk As
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Univ Health Network filed Critical Novo Nordisk As
Publication of MX2017009804A publication Critical patent/MX2017009804A/es
Publication of MX391789B publication Critical patent/MX391789B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017009804A 2015-01-28 2016-01-28 Anticuerpos anti-transtiretina. MX391789B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562109001P 2015-01-28 2015-01-28
US201562266557P 2015-12-11 2015-12-11
PCT/IB2016/050414 WO2016120809A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (2)

Publication Number Publication Date
MX2017009804A MX2017009804A (es) 2018-08-15
MX391789B true MX391789B (es) 2025-03-21

Family

ID=55361912

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009804A MX391789B (es) 2015-01-28 2016-01-28 Anticuerpos anti-transtiretina.

Country Status (19)

Country Link
US (1) US20160257736A1 (cg-RX-API-DMAC7.html)
EP (1) EP3250594B1 (cg-RX-API-DMAC7.html)
JP (2) JP6875280B2 (cg-RX-API-DMAC7.html)
KR (1) KR102619359B1 (cg-RX-API-DMAC7.html)
CN (1) CN107428822B (cg-RX-API-DMAC7.html)
AU (1) AU2016210887B2 (cg-RX-API-DMAC7.html)
CA (1) CA2974911A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017008469A2 (cg-RX-API-DMAC7.html)
CU (1) CU24532B1 (cg-RX-API-DMAC7.html)
EA (1) EA036048B1 (cg-RX-API-DMAC7.html)
ES (1) ES2905311T3 (cg-RX-API-DMAC7.html)
MX (1) MX391789B (cg-RX-API-DMAC7.html)
MY (1) MY193674A (cg-RX-API-DMAC7.html)
PE (1) PE20180200A1 (cg-RX-API-DMAC7.html)
SA (1) SA517381991B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201706125QA (cg-RX-API-DMAC7.html)
TW (2) TWI718121B (cg-RX-API-DMAC7.html)
WO (1) WO2016120809A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201705662B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI718121B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478715A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
EP3691626A4 (en) * 2017-10-06 2021-06-30 Prothena Biosciences Limited METHODS OF DETECTION OF TRANSTHYRETINE
AU2018345806A1 (en) * 2017-10-06 2020-03-12 Novo Nordisk A/S Anti-transthyretin antibodies
PH12020550694A1 (en) 2017-11-29 2021-04-12 Prothena Biosciences Ltd Lyophilized formulation of a monoclonal antibody against transthyretin
WO2020247452A1 (en) * 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
TW202525341A (zh) 2023-12-15 2025-07-01 丹麥商諾佛 儂迪克股份有限公司 穩定的液體調配物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CN100489892C (zh) 1999-02-05 2009-05-20 三星电子株式会社 恢复描述图像的纹理特征的图像纹理描述符的方法及装置
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
AU2002361886A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Antibodies against the muc18 antigen
AU2003302689B2 (en) 2002-11-29 2009-02-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel neomycin phosphotransferase genes and method for the selection of high-producing recombinant cells
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
EP1820022B1 (en) 2004-11-10 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
WO2007124345A2 (en) 2006-04-21 2007-11-01 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
WO2008107388A1 (en) 2007-03-02 2008-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
WO2010030203A1 (en) * 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
US9790269B2 (en) * 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體

Also Published As

Publication number Publication date
CO2017008469A2 (es) 2018-01-16
MX2017009804A (es) 2018-08-15
CA2974911A1 (en) 2016-08-04
BR112017016324A2 (pt) 2018-03-27
AU2016210887B2 (en) 2021-11-04
WO2016120809A1 (en) 2016-08-04
EP3250594A1 (en) 2017-12-06
JP6875280B2 (ja) 2021-05-26
SA517381991B1 (ar) 2021-12-13
MY193674A (en) 2022-10-24
US20160257736A1 (en) 2016-09-08
EP3250594B1 (en) 2021-11-17
PE20180200A1 (es) 2018-01-31
SG11201706125QA (en) 2017-08-30
TWI718121B (zh) 2021-02-11
TWI781507B (zh) 2022-10-21
TW202118782A (zh) 2021-05-16
JP7219928B2 (ja) 2023-02-09
JP2018509889A (ja) 2018-04-12
CU20170096A7 (es) 2018-03-13
KR20170120607A (ko) 2017-10-31
AU2016210887A1 (en) 2017-08-10
EA201791711A1 (ru) 2017-11-30
EA036048B1 (ru) 2020-09-18
ZA201705662B (en) 2018-08-29
KR102619359B1 (ko) 2024-01-02
CN107428822B (zh) 2021-11-23
CN107428822A (zh) 2017-12-01
TW201636372A (zh) 2016-10-16
JP2021129562A (ja) 2021-09-09
ES2905311T3 (es) 2022-04-07
CU24532B1 (es) 2021-07-02

Similar Documents

Publication Publication Date Title
PH12017501318A1 (en) Anti-transthyretin antibodies
SA517381981B1 (ar) أجسام مضادة لترانس ثيرتين
SA517381991B1 (ar) أجسام مضادة لترانس ثيرتين
MX2020003041A (es) Anticuerpos anti-transtiretina.
WO2018007923A3 (en) Anti-transthyretin antibodies
WO2018007924A3 (en) Anti-transthyretin antibodies
WO2018007922A3 (en) Anti-transthyretin antibodies
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
MY210065A (en) Humanized antibody molecules to cd138 and uses thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MY193688A (en) Anti-transthyretin antibodies
HK1240249A1 (en) Anti-transthyretin antibodies
HK1247132A1 (zh) 识别medin的抗体
BR112017007112A2 (pt) compostos de 1,2-benzotiazol para o tratamento de distúrbios renais
EA202090891A1 (ru) Молекулы антител против cd138 и их применение
NZ733896B2 (en) Anti-transthyretin antibodies